Why a new cervical cancer study reinforces the need to move radiation oncology from equipment-driven reimbursement toward total cost of care.

Radiation oncology is entering a fascinating economic period. Technology is becoming more sophisticated, artificial intelligence is moving into treatment planning, adaptive radiotherapy can modify treatment based on daily anatomy, and hypofractionation continues to reduce the number of treatments patients need.

Yet much of our reimbursement structure still assigns value to the individual technical activities required to deliver that care.

A new prospective study of moderately hypofractionated online adaptive radiotherapy (oART) for cervical cancer illustrates why that model is becoming increasingly difficult to sustain. The study is clinically important, but from our perspective at Bridge Oncology, it is equally important as an operations and healthcare economics case study.

It demonstrates why the future value of radiation oncology cannot be determined by how expensive the equipment is or how many technical services we perform. It must increasingly be determined by the total cost and value of treating the patient’s disease.

Fewer Fractions Do Not Necessarily Mean Lower Cost

The study included 30 patients receiving definitive chemoradiotherapy for cervical cancer. Patients received 43.35 Gy in 17 external-beam fractions using daily oART, rather than a more conventional 25-fraction pelvic course.

The clinical findings were encouraging. Adaptation significantly improved target coverage and reduced radiation exposure to several organs at risk. For example, scheduled plans had suboptimal uterine planning-target coverage in 363 of 510 fractions compared with only 21 adapted fractions.

However, achieving those improvements required substantial resources.

Each fraction involved imaging, automated structure generation, physician review and editing, generation of an adapted plan, comparison with the scheduled plan, plan selection, verification imaging, and treatment delivery.

The average treatment required 23 minutes and 18 seconds. Actual beam-on time averaged only 4 minutes and 30 seconds. Contour and organ-at-risk creation and adjustment required more than 12 minutes, while plan creation and selection added approximately four minutes.

That distinction matters.

Moving from 25 fractions to 17 eliminates 32% of treatment visits, but it does not necessarily eliminate 32% of the resources.

Seventeen adaptive treatments at approximately 23.3 minutes each consume roughly 396 minutes of treatment-room occupancy. Twenty-five conventional treatments scheduled at 15 minutes each consume approximately 375 minutes.

The patient receives eight fewer treatments, but the department may not actually create additional machine capacity.

This is why we need to stop equating fewer fractions with lower cost.

Adaptive Therapy Changes the Labor Model

Adaptive therapy also moves the physician into the daily treatment-production process.

The study required physician involvement in target and organ-at-risk review and plan evaluation. At least one radiation oncologist and two radiation therapists participated, with physics support available when needed. The investigators specifically acknowledge the additional personnel, training, equipment, and machine-occupancy requirements of the approach.

That changes the operating model.

The limiting resource in an adaptive program may eventually be neither the vault nor the linear accelerator. It may be the physicians, physicists, and therapists required to support the workflow.

Buying the technology without redesigning staffing can simply create a new and very expensive bottleneck.

The $1,300 Planning Problem

Now consider reimbursement.

For illustration, assume CPT 77301, IMRT treatment planning, is generally billed once per treatment course and produces approximately $1,300 in reimbursement.

A conventional IMRT course may therefore have one major planning process associated with roughly $1,300 of identifiable planning revenue.

Adaptive radiotherapy changes the amount of planning activity without necessarily changing that unit of payment.

In this study, an adaptive planning workflow occurred during every fraction. Targets and organs at risk were reviewed and edited, and an adapted plan was newly optimized using the patient’s daily anatomy.

Seventeen adaptive planning workflows do not suddenly mean seventeen 77301s.

Using the study’s workflow times, contour adjustment plus plan creation and selection consumed approximately 16.5 minutes per fraction. Across 17 fractions, that represents roughly 4.7 hours of adaptive contouring and planning activity per patient, beyond the initial planning process.

Now scale that to 100 patients.

Those patients would generate 1,700 adaptive treatment encounters and approximately 468 hours of adaptive planning workflow.

Meanwhile, using our illustrative assumption, 100 courses would generate approximately $130,000 of identifiable 77301 reimbursement.

The amount of planning work and the unit of reimbursement are already becoming disconnected.

What Happens When 77301 Disappears Into a Case Rate?

Now take the next logical step.

Imagine CMS or another payer establishes a disease-site case rate for radiation therapy.

Simulation, IMRT planning, dosimetry, imaging, physics, adaptive planning, and treatment delivery become components of a predetermined episode payment.

The approximately $1,300 currently identifiable with 77301 may no longer exist as separate revenue.

It becomes part of the case.

Whether the provider performs one plan or 17 adaptive optimizations, the episode payment may remain the same.

That fundamentally changes the economic question.

Under fee-for-service, we often ask:

What can we bill for the additional work?

Under a case rate, we ask:

What does the additional work cost, and does it create enough value to justify that cost?

Planning changes from an identifiable revenue generator into an expense within the episode.

Every additional minute of contouring, physician intervention, physics involvement, machine occupancy, and software utilization consumes part of the case payment.

This Is Why Bridge Oncology Is Bullish on Total Cost of Care

This is precisely why Bridge Oncology has been so bullish in our work with CMS and in advocating for payment reform centered on total cost of care rather than equipment cost.

For too long, radiation oncology has approached reimbursement backward.

A new technology enters the market. The equipment costs more. The service contract costs more. The software costs more. Vendors identify additional technical complexity. The industry then looks toward CMS and commercial payers for reimbursement sufficient to support the cost structure that has already been created.

We have effectively allowed the cost of technology to help determine what reimbursement needs to be.

Cost and value are not the same thing.

If one radiation therapy platform costs $3 million and another costs $6 million, the second platform is not automatically worth twice as much to Medicare or the patient.

The appropriate questions are whether it improves outcomes, reduces toxicity, eliminates unnecessary fractions, prevents downstream utilization, improves access, increases practical capacity, reduces labor, or lowers the total cost of successfully treating the patient’s cancer.

Those questions measure value. The purchase price measures cost.

Total Cost of Care Becomes the Revenue Strategy

Under fee-for-service reimbursement, revenue is largely generated through units of activity.

Under an episode model, that equation reverses.

The case becomes the unit of revenue. Everything required to treat the patient becomes an expense against that revenue.

That makes total cost of care more than a payer concept. It becomes the provider’s revenue strategy.

It also changes the vendor relationship.

If the case rate is fixed, hospitals cannot continually absorb higher equipment prices, software fees, and service contracts and expect CMS to create another code or increase reimbursement to compensate.

The pressure must move upstream.

Health systems should increasingly be asking vendors:

If your technology is going to be part of this episode, show us how it improves the clinical and economic performance of the episode.

That might mean lower acquisition costs, automated contouring, less physician intervention, shorter treatment-room occupancy, fewer fractions, fewer complications, or lower downstream healthcare utilization.

The burden cannot continually fall on the payer to increase reimbursement because the equipment became more expensive.

Adaptive Radiotherapy Could Prove the Model

None of this is an argument against adaptive radiotherapy.

It is an argument for valuing it correctly.

Imagine adaptive technology allowing us to move from 25 fractions to 17 while automation reduces 12 minutes of contour review to four. Imagine physician intervention becoming increasingly exception based. Imagine measurable reductions in toxicity and downstream utilization. Imagine hypofractionation and automation allowing a department to treat more patients without constructing another vault.

Now the technology is not simply more sophisticated.

It is reducing the total resources required to produce an excellent cancer outcome.

That is innovation capable of thriving under total-cost-of-care reimbursement.

Radiation oncology is moving toward fewer fractions, adaptive planning, AI, automation, and increasingly intelligent treatment delivery. Payment is simultaneously moving toward episodes, outcomes, efficiency, and accountability.

The industry has a choice.

We can continue arguing that reimbursement should rise because our machines, software, and service contracts cost more.

Or we can demonstrate the extraordinary value radiation oncology creates by treating cancer more effectively, efficiently, and sustainably.

At Bridge Oncology, we believe the second argument is considerably stronger.

The sustainable revenue generator of the future should not be the cost of the machine, the number of fractions delivered, or the number of CPT codes generated. It should be the value created by successfully treating the patient’s cancer at an appropriate total cost of care.

Adaptive Radiotherapy Is Advancing Faster Than Its Economics—and That Is the Point

Why a new cervical cancer study reinforces the need to move radiation oncology from equipment-driven reimbursement toward total cost of care.

Radiation oncology is entering a fascinating economic period. Technology is becoming more sophisticated, artificial intelligence is moving into treatment planning, adaptive radiotherapy can modify treatment based on daily anatomy, and hypofractionation continues to reduce the number of treatments patients need.

Yet much of our reimbursement structure still assigns value to the individual technical activities required to deliver that care.

A new prospective study of moderately hypofractionated online adaptive radiotherapy (oART) for cervical cancer illustrates why that model is becoming increasingly difficult to sustain. The study is clinically important, but from our perspective at Bridge Oncology, it is equally important as an operations and healthcare economics case study.

It demonstrates why the future value of radiation oncology cannot be determined by how expensive the equipment is or how many technical services we perform. It must increasingly be determined by the total cost and value of treating the patient’s disease.

Fewer Fractions Do Not Necessarily Mean Lower Cost

The study included 30 patients receiving definitive chemoradiotherapy for cervical cancer. Patients received 43.35 Gy in 17 external-beam fractions using daily oART, rather than a more conventional 25-fraction pelvic course.

The clinical findings were encouraging. Adaptation significantly improved target coverage and reduced radiation exposure to several organs at risk. For example, scheduled plans had suboptimal uterine planning-target coverage in 363 of 510 fractions compared with only 21 adapted fractions.

However, achieving those improvements required substantial resources.

Each fraction involved imaging, automated structure generation, physician review and editing, generation of an adapted plan, comparison with the scheduled plan, plan selection, verification imaging, and treatment delivery.

The average treatment required 23 minutes and 18 seconds. Actual beam-on time averaged only 4 minutes and 30 seconds. Contour and organ-at-risk creation and adjustment required more than 12 minutes, while plan creation and selection added approximately four minutes.

That distinction matters.

Moving from 25 fractions to 17 eliminates 32% of treatment visits, but it does not necessarily eliminate 32% of the resources.

Seventeen adaptive treatments at approximately 23.3 minutes each consume roughly 396 minutes of treatment-room occupancy. Twenty-five conventional treatments scheduled at 15 minutes each consume approximately 375 minutes.

The patient receives eight fewer treatments, but the department may not actually create additional machine capacity.

This is why we need to stop equating fewer fractions with lower cost.

Adaptive Therapy Changes the Labor Model

Adaptive therapy also moves the physician into the daily treatment-production process.

The study required physician involvement in target and organ-at-risk review and plan evaluation. At least one radiation oncologist and two radiation therapists participated, with physics support available when needed. The investigators specifically acknowledge the additional personnel, training, equipment, and machine-occupancy requirements of the approach.

That changes the operating model.

The limiting resource in an adaptive program may eventually be neither the vault nor the linear accelerator. It may be the physicians, physicists, and therapists required to support the workflow.

Buying the technology without redesigning staffing can simply create a new and very expensive bottleneck.

The $1,300 Planning Problem

Now consider reimbursement.

For illustration, assume CPT 77301, IMRT treatment planning, is generally billed once per treatment course and produces approximately $1,300 in reimbursement.

A conventional IMRT course may therefore have one major planning process associated with roughly $1,300 of identifiable planning revenue.

Adaptive radiotherapy changes the amount of planning activity without necessarily changing that unit of payment.

In this study, an adaptive planning workflow occurred during every fraction. Targets and organs at risk were reviewed and edited, and an adapted plan was newly optimized using the patient’s daily anatomy.

Seventeen adaptive planning workflows do not suddenly mean seventeen 77301s.

Using the study’s workflow times, contour adjustment plus plan creation and selection consumed approximately 16.5 minutes per fraction. Across 17 fractions, that represents roughly 4.7 hours of adaptive contouring and planning activity per patient, beyond the initial planning process.

Now scale that to 100 patients.

Those patients would generate 1,700 adaptive treatment encounters and approximately 468 hours of adaptive planning workflow.

Meanwhile, using our illustrative assumption, 100 courses would generate approximately $130,000 of identifiable 77301 reimbursement.

The amount of planning work and the unit of reimbursement are already becoming disconnected.

What Happens When 77301 Disappears Into a Case Rate?

Now take the next logical step.

Imagine CMS or another payer establishes a disease-site case rate for radiation therapy.

Simulation, IMRT planning, dosimetry, imaging, physics, adaptive planning, and treatment delivery become components of a predetermined episode payment.

The approximately $1,300 currently identifiable with 77301 may no longer exist as separate revenue.

It becomes part of the case.

Whether the provider performs one plan or 17 adaptive optimizations, the episode payment may remain the same.

That fundamentally changes the economic question.

Under fee-for-service, we often ask:

What can we bill for the additional work?

Under a case rate, we ask:

What does the additional work cost, and does it create enough value to justify that cost?

Planning changes from an identifiable revenue generator into an expense within the episode.

Every additional minute of contouring, physician intervention, physics involvement, machine occupancy, and software utilization consumes part of the case payment.

This Is Why Bridge Oncology Is Bullish on Total Cost of Care

This is precisely why Bridge Oncology has been so bullish in our work with CMS and in advocating for payment reform centered on total cost of care rather than equipment cost.

For too long, radiation oncology has approached reimbursement backward.

A new technology enters the market. The equipment costs more. The service contract costs more. The software costs more. Vendors identify additional technical complexity. The industry then looks toward CMS and commercial payers for reimbursement sufficient to support the cost structure that has already been created.

We have effectively allowed the cost of technology to help determine what reimbursement needs to be.

Cost and value are not the same thing.

If one radiation therapy platform costs $3 million and another costs $6 million, the second platform is not automatically worth twice as much to Medicare or the patient.

The appropriate questions are whether it improves outcomes, reduces toxicity, eliminates unnecessary fractions, prevents downstream utilization, improves access, increases practical capacity, reduces labor, or lowers the total cost of successfully treating the patient’s cancer.

Those questions measure value. The purchase price measures cost.

Total Cost of Care Becomes the Revenue Strategy

Under fee-for-service reimbursement, revenue is largely generated through units of activity.

Under an episode model, that equation reverses.

The case becomes the unit of revenue. Everything required to treat the patient becomes an expense against that revenue.

That makes total cost of care more than a payer concept. It becomes the provider’s revenue strategy.

It also changes the vendor relationship.

If the case rate is fixed, hospitals cannot continually absorb higher equipment prices, software fees, and service contracts and expect CMS to create another code or increase reimbursement to compensate.

The pressure must move upstream.

Health systems should increasingly be asking vendors:

If your technology is going to be part of this episode, show us how it improves the clinical and economic performance of the episode.

That might mean lower acquisition costs, automated contouring, less physician intervention, shorter treatment-room occupancy, fewer fractions, fewer complications, or lower downstream healthcare utilization.

The burden cannot continually fall on the payer to increase reimbursement because the equipment became more expensive.

Adaptive Radiotherapy Could Prove the Model

None of this is an argument against adaptive radiotherapy.

It is an argument for valuing it correctly.

Imagine adaptive technology allowing us to move from 25 fractions to 17 while automation reduces 12 minutes of contour review to four. Imagine physician intervention becoming increasingly exception based. Imagine measurable reductions in toxicity and downstream utilization. Imagine hypofractionation and automation allowing a department to treat more patients without constructing another vault.

Now the technology is not simply more sophisticated.

It is reducing the total resources required to produce an excellent cancer outcome.

That is innovation capable of thriving under total-cost-of-care reimbursement.

Radiation oncology is moving toward fewer fractions, adaptive planning, AI, automation, and increasingly intelligent treatment delivery. Payment is simultaneously moving toward episodes, outcomes, efficiency, and accountability.

The industry has a choice.

We can continue arguing that reimbursement should rise because our machines, software, and service contracts cost more.

Or we can demonstrate the extraordinary value radiation oncology creates by treating cancer more effectively, efficiently, and sustainably.

At Bridge Oncology, we believe the second argument is considerably stronger.

The sustainable revenue generator of the future should not be the cost of the machine, the number of fractions delivered, or the number of CPT codes generated. It should be the value created by successfully treating the patient’s cancer at an appropriate total cost of care.